Short Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Increases By 64.3%

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totaling 40,719 shares, a growth of 64.3% from the December 31st total of 24,781 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average trading volume of 51,051 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 51,051 shares, the short-interest ratio is currently 0.8 days. Approximately 0.8% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of research firms have commented on NEUP. Zacks Research downgraded shares of Neuphoria Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 23rd. Finally, HC Wainwright reduced their price objective on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, December 5th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $21.00.

Hedge Funds Weigh In On Neuphoria Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new position in Neuphoria Therapeutics in the fourth quarter worth about $102,000. Millennium Management LLC acquired a new position in Neuphoria Therapeutics in the third quarter worth $216,000. Finally, Persistent Asset Partners Ltd acquired a new position in Neuphoria Therapeutics during the 3rd quarter worth about $58,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Price Performance

NASDAQ NEUP remained flat at $4.02 during trading on Friday. The company’s stock had a trading volume of 21,692 shares, compared to its average volume of 45,678. The business’s 50 day simple moving average is $4.08 and its two-hundred day simple moving average is $7.58. Neuphoria Therapeutics has a one year low of $3.64 and a one year high of $21.40. The company has a market cap of $21.63 million, a P/E ratio of -0.82 and a beta of 0.51.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its earnings results on Friday, November 14th. The company reported ($4.41) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, equities research analysts predict that Neuphoria Therapeutics will post -1.56 EPS for the current fiscal year.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.